Literature DB >> 26953557

Decreased physical activity, reduced QoL and presence of debilitating fatigue in patients with Addison's disease.

Eline S van der Valk1, Lisanne C C J Smans2, Hedwig Hofstetter3, Janine H Stubbe4, Marieke de Vries2, Frank J G Backx5, Ad R M M Hermus6, Pierre M J Zelissen2.   

Abstract

BACKGROUND: Health-related quality of life in patients with Addison's disease has been assessed in various European countries, indicating a reduced quality of life. However, no studies have addressed the impact of Addison's disease on physical activity.
OBJECTIVE: The aim of this study was to investigate the quality of life in Dutch patients with Addison's disease particularly regarding the presence of fatigue and the ability to be physically active.
METHODS: In this cross-sectional study, a postal survey was performed among Dutch patients with Addison's disease on stable glucocorticoid replacement therapy with hydrocortisone or cortisone acetate. For quality of life and physical activity assessment, patients completed general and health-related quality of life and physical activity questionnaires, and scores were compared to Dutch controls.
RESULTS: A total of 328 patients with Addison's disease were studied. In patients with Addison's disease, only 45·7% met the standard of physical activity (Combinorm) compared to 67·8% of Dutch controls (P < 0·01). Forty-eight per cent of patients showed abnormal fatigue, while 61% had severe fatigue. The CIS fatigue scores were significantly higher compared to controls (P < 0·01). We found reduced general subjective health-related QoL scores in both male and female patients, especially in younger patients <65 years of age.
CONCLUSION: Physical activity is decreased in patients with Addison's disease, combined with a reduced subjective health-related QoL and increased fatigue.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26953557     DOI: 10.1111/cen.13059

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study.

Authors:  Anna G Nilsson; Ragnhildur Bergthorsdottir; Pia Burman; Per Dahlqvist; Bertil Ekman; Britt Edén Engström; Oskar Ragnarsson; Stanko Skrtic; Jeanette Wahlberg; Heinrich Achenbach; Sharif Uddin; Claudio Marelli; Gudmundur Johannsson
Journal:  Eur J Endocrinol       Date:  2017-03-14       Impact factor: 6.664

Review 2.  Sleep, Cognition and Cortisol in Addison's Disease: A Mechanistic Relationship.

Authors:  Michelle Henry; Kevin Garth Flusk Thomas; Ian Louis Ross
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-27       Impact factor: 5.555

3.  Sex-Specific Limitations in Physical Health in Primary Adrenal Insufficiency.

Authors:  Nora Møller Didriksen; Åse Bjorvatn Sævik; Linn Solveig Sortland; Marianne Øksnes; Eystein Sverre Husebye
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-18       Impact factor: 5.555

4.  Ultradian rhythmicity of plasma cortisol is necessary for normal emotional and cognitive responses in man.

Authors:  K Kalafatakis; G M Russell; C J Harmer; M R Munafo; N Marchant; A Wilson; J C Brooks; C Durant; J Thakrar; P Murphy; N J Thai; S L Lightman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-09       Impact factor: 11.205

Review 5.  Dynamics of ACTH and Cortisol Secretion and Implications for Disease.

Authors:  Stafford L Lightman; Matthew T Birnie; Becky L Conway-Campbell
Journal:  Endocr Rev       Date:  2020-06-01       Impact factor: 19.871

Review 6.  Clinical Unmet Needs in the Treatment of Adrenal Crisis: Importance of the Patient's Perspective.

Authors:  Kim M J A Claessen; Cornelie D Andela; Nienke R Biermasz; Alberto M Pereira
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-20       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.